Artelo Biosciences
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ARTL and other ETFs, options, and stocks.About ARTL
Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal.
CEOGregory D. Gorgas
CEOGregory D. Gorgas
Employees6
Employees6
HeadquartersSolana Beach, California
HeadquartersSolana Beach, California
Founded2011
Founded2011
Employees6
Employees6
ARTL Key Statistics
Market cap6.18M
Market cap6.18M
Price-Earnings ratio-0.25
Price-Earnings ratio-0.25
Dividend yield—
Dividend yield—
Average volume160.59K
Average volume160.59K
High today$4.79
High today$4.79
Low today$4.53
Low today$4.53
Open price$4.60
Open price$4.60
Volume123.70K
Volume123.70K
52 Week high$28.60
52 Week high$28.60
52 Week low$4.20
52 Week low$4.20
ARTL News
Seeking Alpha 6d
Artelo Biosciences announces pricing of $3 million public offeringHealthcare On the Move Artelo Biosciences announces pricing of $3 million public offering Sep. 04, 2025 8:47 AM ET Artelo Biosciences, Inc. (ARTL) Stock By: Ti...
TipRanks 6d
Artelo Biosciences announces common stock, warrant offering, no amount givenArtelo Biosciences (ARTL) announced it has commenced an underwritten public offering of its common stock and/or pre-funded warrants. All shares of common stock...
TipRanks 7d
Artelo Biosciences announces interim Phase 2 CAReS resultsArtelo Biosciences (ARTL) announced interim results from its Phase 2 Cancer Appetite Recovery Study trial with ART27.13, the Company’s peripherally acting canna...
People also own
Based on the portfolios of people who own ARTL. This list is generated using Robinhood data, and it’s not a recommendation.